

| | |
|-------------------------|---|
| 1. Record Nr. | UNINA9910144561603321 |
| Titolo | Novel therapeutic proteins [[electronic resource]] : selected case studies // edited by Klaus Dembowsky and Peter Stadler |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2001 |
| ISBN | 1-281-76404-3 9786611764043 3-527-61302-1 3-527-61303-X |
| Descrizione fisica | 1 online resource (388 p.) |
| Altri autori (Persone) | StadlerPeter, Dr. DembowskyKlaus |
| Disciplina | 615.3 660.6 |
| Soggetti | Gene therapy Recombinant proteins Electronic books. |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Note generali | Description based upon print version of record. |
| Nota di bibliografia | Includes bibliographical references and index. |
| Nota di contenuto | Novel Therapeutic Proteins; Foreword; Preface; Contents; Introduction and Overview; 1 Medical Applications of Recombinant Proteins in Humans; 1.1 Introduction; 1.2 Presently Approved Biotech Products; 1.3 Biotechnology Products in Clinical Development; 1.4 Specific Diseases and Applications; 1.4.1 Myocardial Infarction and Stroke; 1.4.2 Heart Failure; 1.4.3 Fibrosis; 1.4.4 Osteoporosis; 1.4.5 Obesity, Insulin Resistance, and Non-Insulin Dependent (Type II) Diabetes; 1.4.6 Sepsis; 1.4.7 Immunoenhancement; 1.4.7.1 Tumor Therapy; 1.4.7.2 Vaccines; 1.4.8 Immune Deviation 1.4.9 Multiple Sclerosis (MS)1.4.10 Psoriasis; 1.4.11 Arthritis; 1.4.12 Inflammatory Bowel Disease; 1.4.13 Allergy and Asthma; 1.4.14 Replacement Therapies; 1.4.15 Viral Infections; 1.4.16 Reproductive Medicine .; 1.4.17 Other; 1.5 Conclusion; 1.6 References; Recombinant Hormones; 2 Clinical Applications of Recombinant Human Erythropoietin; 2.1 Structure of Human Erythropoietin; 2.2 General Principles; 2.3 Medical Applications of Recombinant Human EPO; 2.3.1 |

The Anemia of Chronic Renal Failure (CRF); 2.3.2 Acquired Immunodeficiency Syndrome (AIDS)
2.3.3 Chemotherapy Induced Anemia of Non-Hematologic Malignancies
2.3.4 The Perioperative Setting; 2.3.4.1 Recombinant Human EPO without Autologous Blood Donation; 2.3.4.2 Recombinant Human EPO as an Adjunct to Autologous Blood Donation; 2.3.5 The Anemia of Prematurity; 2.3.6 The Anemia of Hematologic Malignancies; 2.3.7 Myelodysplastic Syndromes and Other Hematologic Stem Cell Disorders; 2.3.8 Bone Marrow Transplantation (BMT); 2.3.9 The Hemoglobinopathies; 2.3.10 The Anemia of Chronic Inflammation; 2.4 Patient Response and Medical Economics
2.5 Pharmacokinetics : Dosage, Routes of Administration. and Effect Monitoring
2.6 Iron Supplementation during rhEPO Treatment; 2.7 Future Directions; 2.8 References; 3 Human Recombinant Growth Hormone; 3.1 Introduction; 3.2 Hypothalamic Regulation; 3.2.1 Somatostatin; 3.2.2 Growth Hormone Releasing Hormone; 3.2.3 Other Neurotransmitters; 3.3 Peripheral Regulation of GH; 3.4 Mechanisms of Action of GH; 3.4.1 GH Receptor; 3.4.2 Metabolic Effects; 3.4.3 Insulin Growth Factors (IGF); 3.4.3.1 Circulation of IGF; 3.4.3.2 Receptors of IGF; 3.4.3.3 Actions of IGF; 3.5 GH Effects on Growth
3.5.1 Dwarfism 3.5.2 Gigantism; 3.5.3 Acromegaly; 3.5.4 GH Deficiency in the Adult; 3.6 Production of GH; 3.6.1 Preparations Obtained by Extractions; 3.6.2 Genetic Engineering of GH; 3.6.2.1 Synthesis in Prokaryotic Cells; 3.6.2.2 Second Synthetic Procedure for GH Synthesis; 3.6.2.3 Third Synthetic Procedure for GH Synthesis; 3.6.2.4 Synthesis of hGH in Eukaryotic Cells; 3.7 Therapy with GH; 3.7.1 Use of rhGH in the Treatment of GH Deficiency; 3.7.2 Use of rhGH in Chronic Renal Failure (CRF); 3.7.3 Use of rhGH in Turner's Syndrome; 3.7.4 Use of GH in Different Catabolic States and in AIDS
3.8 References

Sommario/riassunto

This book describes medical applications of recombinant proteins and monoclonal antibodies, some of which have already been on the market for several years while others have only recently been launched. It also highlights the manufacturing processes for individual products, the strategies that were taken by companies in the clinical development, and the hurdles that were encountered in clinical trials and had to be overcome before approval by regulatory authorities. Finally, this book illustrates strategies to modify and improve the pharmacodynamic and pharmacokinetic properties of naturally o
